Luke Breaks Down Key Clinical Trial Updates From the 2023 ASCO Annual Meeting

Source: OncLive, July 2023

Jason Luke, MD, FACP, discusses key takeaways from the KEYNOTE-716 and KEYNOTE-942 trials and other key updates from across the melanoma landscape presented at the 2023 ASCO Annual Meeting.

Updated data from the phase 3 KEYNOTE-716 (NCT03553836) presented at the 2023 ASCO Annual Meeting highlighted the continued evolution of the adjuvant treatment setting for patients with melanoma, according to Jason Luke, MD, FACP.

Results from final distant metastasis­–free survival (DMFS) analysis of the phase 3 study showed that at a median follow-up of 39.4 months, patients with stage IIB or IIC melanoma treated with adjuvant pembrolizumab (Keytruda) and those given placebo experienced a median DMFS that was not yet reached (HR, 0.59; 95% CI, 0.44-0.79). The 36-month DMFS rate was 84.4% in the pembrolizumab arm compared with 74.7% in the placebo arm.